MODULE 6 EXAM NM701 ACTUAL QUESTIONS AND ANSWERS
WITH COMPLETE SOLUTIONS 100% GUARANTEED PASS
In a Clinical Breast Exam (CBE), what qualifies as a “dominant mass?” (2 points)
1. 3-dimensional structure
2. Its texture is different from surrounding soft/fatty tissue and firmer
glandular/structural tissue
During a CBE, if a mass is hard, is it more or less worrisome?
MORE worrisome
During a CBE, if a mass is tender, is it more or less worrisome?
Often LESS worrisome
During a CBE, if a mass is soft, is it more or less worrisome?
Often LESS worrisome
During a CBE, if a mass is fixed, is it more or less worrisome?
MORE worrisome
During a CBE, if a mass is smooth, is it more or less worrisome?
Often LESS worrisome
During a CBE, if a mass has rough edges, is it more or less worrisome?
MORE worrisome
During a CBE, if a mass is mobile, is it more or less worrisome?
Often LESS worrisome
If breast discharge is bilateral, is it more or less worrisome?
,Less worrisome
If breast discharge is Elicited by squeezing, is it more or less worrisome?
Less worrisome
If breast discharge is clear, is it more or less worrisome?
MORE worrisome
If breast discharge is green, is it more or less worrisome?
Less worrisome
How should you document a mass found in a CBE? (6)
1. Which breast
2. Location on the clock face
3. Distance in mm/cm from the nipple
4. Size and diameter in mm/cm
5. Mass characteristics
6. Presence or absence of axillary lymphadenopathy
List the mass characteristics you would document (5)
1. Shape
2. Consistency
3. Tenderness
4. Mobility
5. Borders
During a CBE what should we worry about? (4)
1. Masses with suspicious features in a woman of any age
2. Any palpable masses in a post-menopausal women
, 3. Nipple “eczema”
4. Inflammatory CA symptoms
a. Red, edematous skin that looks like mastitis
b. Peau d’orange
Give BI-RADS Categories (6)
0. (incomplete): recommended additional imaging -mammogram or targeted US
1. (negative): routine breast MR screening if cumulative lifetime risk >/= 20%
2. (benign): routine breast MR screening if cumulative lifetime risk >/= 20%
3. (probably benign): short-interval (6-month) follow-up
4. (suspicious): tissue diagnosis
5. (highly suggestive of malignancy): tissue diagnosis
6. (known biopsy-proven malignancy): surgical excision when clinically appropriate
What are the 2023 USPSTF recommendations for breast cancer screening? (2)
1. Start screening average-risk women at age 40 every 2 years.
2. This may have a higher benefit-to-risk ratio for black women who have a higher
prevalence of invasive breast cancer.
Are breast ultrasounds recommended for routine screening? (4 points)
1. First-line diagnosis in palpated masses for women under 30 (add diagnostic
mammography if mass feels suspicious).
2. Used adjunctively to characterize radiologically-identified masses (e.g., solid vs.
cystic)
3. No benefit to routine adjunctive use with all mammograms.
WITH COMPLETE SOLUTIONS 100% GUARANTEED PASS
In a Clinical Breast Exam (CBE), what qualifies as a “dominant mass?” (2 points)
1. 3-dimensional structure
2. Its texture is different from surrounding soft/fatty tissue and firmer
glandular/structural tissue
During a CBE, if a mass is hard, is it more or less worrisome?
MORE worrisome
During a CBE, if a mass is tender, is it more or less worrisome?
Often LESS worrisome
During a CBE, if a mass is soft, is it more or less worrisome?
Often LESS worrisome
During a CBE, if a mass is fixed, is it more or less worrisome?
MORE worrisome
During a CBE, if a mass is smooth, is it more or less worrisome?
Often LESS worrisome
During a CBE, if a mass has rough edges, is it more or less worrisome?
MORE worrisome
During a CBE, if a mass is mobile, is it more or less worrisome?
Often LESS worrisome
If breast discharge is bilateral, is it more or less worrisome?
,Less worrisome
If breast discharge is Elicited by squeezing, is it more or less worrisome?
Less worrisome
If breast discharge is clear, is it more or less worrisome?
MORE worrisome
If breast discharge is green, is it more or less worrisome?
Less worrisome
How should you document a mass found in a CBE? (6)
1. Which breast
2. Location on the clock face
3. Distance in mm/cm from the nipple
4. Size and diameter in mm/cm
5. Mass characteristics
6. Presence or absence of axillary lymphadenopathy
List the mass characteristics you would document (5)
1. Shape
2. Consistency
3. Tenderness
4. Mobility
5. Borders
During a CBE what should we worry about? (4)
1. Masses with suspicious features in a woman of any age
2. Any palpable masses in a post-menopausal women
, 3. Nipple “eczema”
4. Inflammatory CA symptoms
a. Red, edematous skin that looks like mastitis
b. Peau d’orange
Give BI-RADS Categories (6)
0. (incomplete): recommended additional imaging -mammogram or targeted US
1. (negative): routine breast MR screening if cumulative lifetime risk >/= 20%
2. (benign): routine breast MR screening if cumulative lifetime risk >/= 20%
3. (probably benign): short-interval (6-month) follow-up
4. (suspicious): tissue diagnosis
5. (highly suggestive of malignancy): tissue diagnosis
6. (known biopsy-proven malignancy): surgical excision when clinically appropriate
What are the 2023 USPSTF recommendations for breast cancer screening? (2)
1. Start screening average-risk women at age 40 every 2 years.
2. This may have a higher benefit-to-risk ratio for black women who have a higher
prevalence of invasive breast cancer.
Are breast ultrasounds recommended for routine screening? (4 points)
1. First-line diagnosis in palpated masses for women under 30 (add diagnostic
mammography if mass feels suspicious).
2. Used adjunctively to characterize radiologically-identified masses (e.g., solid vs.
cystic)
3. No benefit to routine adjunctive use with all mammograms.
